DDReg Knowledge Capsule

This episode explores why Egypt is a top priority for regional expansion, boasting a pharmaceutical sector valued at approximately USD 5.9 billion. We dive into the regulatory framework established by Law No. 151 of 2019, which transitioned authority to the Egyptian Drug Authority (EDA).The discussion covers the essential 10-step authorization process, the mandatory requirement for a locally licen...

This episode provides a comprehensive guide to the Therapeutic Goods Act 1989, exploring the various pathways for getting prescription medicines onto the Australian Register of Therapeutic Goods (ARTG). We dive into the differences between Standard, Verification, and Priority Review pathways, while highlighting the critical importance of Australian-specific documentation, such as the Australian Sp...

In this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the goal of incentivising development for niche populations, they differ significantly in their prevalence thresholds, eligibility criteria, and financial...

In this episode, we explore the significant transformation of the medical device landscape in Sri Lanka under the mandate of the NMRA. We break down the risk-based classification system—from low-risk Class One items like bandages to the high-risk apex of Class Three devices like cardiac stents. Learn how international manufacturers can leverage the Global Recognition Pathway to fast-track approval...

This episode explores the significant 2026 updates to the Ministry of Food and Drug Safety (MFDS) drug registration process in South Korea. We dive into the relaxation of mandatory domestic clinical trials in favour of multinational Phase 3 data, the expansion of the conditional approval pathway for innovative medicines, and the increasing alignment of biosimilar frameworks with international stan...

In this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration process, from the mandatory appointment of a Saudi Authorized Representative (SAR) to the technical nuances of submitting eCTD-compliant dossiers. The...

This podcast, Episode [32], introduced with the "DDReg Knowledge capsule" greeting, provides a deep dive into the complexities of pharmaceutical registration in Brazil. It explores the central role of ANVISA (National Health Surveillance Agency) and the specific regulatory pathways designed to accelerate market entry, such as Priority Review and the Reliance and Expedited Pathway. The discussion c...

Welcome to this episode of the DDReg Knowledge Capsule, Episode [31] where we explore the critical role of Standard Operating Procedures (SOPs) as the foundation of a reliable pharmacovigilance (PV) system. This discussion highlights how well-written SOPs transform global regulatory requirements from agencies such as the EMA, FDA, and CDSCO into actionable workflows that ensure patient safety and...

📢 DDReg Knowledge Capsule – Episode [30]This podcast provides an in-depth analysis of Indonesia's regulatory landscape, the largest pharmaceutical market in Southeast Asia, with a population exceeding 270 million. It details the methodical and documentation-intensive drug registration process managed by the National Agency of Drug and Food Control (BPOM). Key insights include the mandatory requir...

📢 DDReg Knowledge Capsule – Episode [29]The shift in global healthcare as digital tools move from experimental pilots to core national infrastructure. It highlights the collaborative roles of the World Health Organisation (WHO), which defines the strategic policy framework, and the Global Initiative on Digital Health (GIDH), which manages the practical implementation and funding. The 2027 strateg...

📢 DDReg Knowledge Capsule – Episode [28]This podcast covers the analysis of the regulatory complexities involved when relocating production facilities for pharmaceuticals, biologics, and medical devices. Moving a manufacturing site is not a simple logistical task but a significant material change that requires specific approvals and notifications across different global jurisdictions. The text hi...

📢 DDReg Knowledge Capsule – Episode [27]This podcast covers Post-Market Clinical Follow-up (PMCF) under the European Union’s Medical Device Regulation (MDR). It describes how manufacturers must transition from passive monitoring to a continuous, proactive process of gathering clinical data throughout a product’s entire lifecycle. The source outlines the necessity of creating defensible documentat...

📢 DDReg Knowledge Capsule – Episode [26]This podcast cover about how ethnic sensitivity influences the creation and approval of pharmaceuticals on a global scale. It highlights that biological differences, such as genetics and metabolism, alongside extrinsic factors like diet and environment, can significantly alter a medication’s safety and performance. To address these variations, regulatory bo...

📢 DDReg Knowledge Capsule – Episode [25]This podcast cover about ICH E5 guidelines mandate bridging studies when foreign clinical data cannot reliably predict a drug's safety or efficacy in a local population. Requirements depend on ethnic sensitivity, including intrinsic genetic factors, extrinsic medical practices, and PK/PD differences. https://resource.ddregpharma.com/blogs/bridging-studies-m...

📢 DDReg Knowledge Capsule – Episode [24]How cultural influences create significant discrepancies in adverse event reporting and patient-reported outcomes within global pharmacovigilance. It highlights that inconsistencies in safety data often stem from social norms, language barriers, and varying levels of health literacy rather than just regulatory failures. The source warns that these nuances c...

📢 DDReg Knowledge Capsule – Episode [23]importance of maintaining rigorous oversight of external vendors within the international pharmaceutical and medical device sectors. It explains that regulatory bodies hold the primary product owners directly accountable for any quality failures, regardless of where manufacturing or material sourcing occurs. To mitigate these risks, the source advocates for...

📢 DDReg Knowledge Capsule – Episode [22]Designing clinical trials specifically for advanced medicinal products such as gene and cell therapies. Because these treatments possess unique biological complexities, the source emphasizes that standard drug development frameworks are often insufficient and require specialised regulatory alignment. It highlights the importance of using adaptive dosing str...

📢 DDReg Knowledge Capsule – Episode [22] Failure Mode and Effects Analysis (FMEA) as a dynamic tool for managing medical device risks throughout their entire lifespan. Rather than treating it as a one-time paperwork requirement, the source advocates for a comprehensive framework that evolves alongside design, manufacturing, and real-world usage. It details how different types of analysis, such as...

📢 DDReg Knowledge Capsule – Episode [21] Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust, necessitating that automated systems be audited with the same rigor as traditional validated processes. Regulatory authorities now require demonstrable...

📢 DDReg Knowledge Capsule – Episode [20] Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust, necessitating that automated systems be audited with the same rigor as traditional validated processes. Regulatory authorities now require demonstrable...

📢 DDReg Knowledge Capsule – Episode [20]Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust, necessitating that automated systems be audited with the same rigor as traditional validated processes. Regulatory authorities now require demonstrable...

📢 DDReg Knowledge Capsule – Episode [19]These products, which often exhibit characteristics overlapping categories like medicines, medical devices, and food supplements, present a significant challenge because misclassification carries substantial compliance risks and can severely delay market entry. Regulatory authorities determine the necessary classification pathway—which dictates obligations...

📢 DDReg Knowledge Capsule – Episode [18]Hong Kong is transitioning from the Medical Device Administrative Control System (MDACS), a voluntary listing mechanism, to a new statutory mandatory registration system. This significant shift is driven by the Department of Health’s goal to strengthen patient safety and align with mature international regulatory frameworks by requiring comprehensive techni...

📢 DDReg Knowledge Capsule – Episode [17]The significant global shift toward eCTD 4.0 for regulatory dossier submissions in the pharmaceutical industry. This new standard moves regulatory management from static files to a data-driven connected information system, emphasising features like a unified XML backbone, unique document identifiers (UUIDs), and controlled vocabularies. The article outlines...

📢 DDReg Knowledge Capsule – Episode [16]Role of the Qualified Person Responsible for Pharmacovigilance (QPPV) in the European Union (EU). It clarifies that the QPPV services is a legally mandated strategic leader for every Marketing Authorisation Holder, continuously ensuring the safety and benefit-risk profile of marketed medicines in line with EU pharmacovigilance (PV) legislation. The article...